Innate Pharma (NASDAQ:IPHYF) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Zacks has also given Innate Pharma an industry rank of 77 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded Innate Pharma from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Wednesday, February 8th.
Shares of Innate Pharma (NASDAQ:IPHYF) traded up 0.45% on Tuesday, reaching $11.25. The company’s stock had a trading volume of 206 shares. Innate Pharma has a 52-week low of $10.36 and a 52-week high of $16.55. The company has a 50 day moving average price of $12.03 and a 200 day moving average price of $13.18. The company has a market cap of $606.20 million and a P/E ratio of 45.92.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2486275/innate-pharma-iphyf-receives-average-recommendation-of-strong-buy-from-analysts.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.